Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
|Articles|September 1, 1996
The American Journal of Managed Care
- September 1996
- Volume 2
- Issue 8
Determinants of Hospital Charges and Costs in Acute Myocardial Infarction: A Report from the Myocardial Infarction Cost Study (MICS) Group
Advertisement
Articles in this issue
about 30 years ago
Potential Cost-Effectiveness of Acute Stroke Treatmentabout 30 years ago
Potential for SSRIs as Monotherapy for Comorbid Psychiatric Disordersabout 30 years ago
Establishing the Basis for Successful Disease Management Contractingabout 30 years ago
Accreditation Standards in Managed Careabout 30 years ago
A Closer Look at CapitationAdvertisement
Related to this article
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Using Complement Inhibitors in GA Comes With Pros and Cons
5